High lipoprotein(a) levels are associated with long-term adverse outcomes in acute myocardial infarction patients in high Killip classes

Korean Circulation Journal

Volumn 40, Issue 10, 2010, Pages 491-498

  Cho, Jae Yeong ^a   Jeong, Myung Ho ^a   Ahn, Youngkeun ^a   Hong, Young Joon ^a   Park, Hyung Wook ^a   Yoon, Nam Sik ^a   Yoon, Hyun Ju ^a   Kim, Kye Hun ^a   Kim, Ju Han ^a   Cho, Jeong Gwan ^a   Park, Jong Chun ^a   Kang, Jung Chaee ^a  

^a Chonnam National University   (South Korea)

Author keywords

Lipoproteins; Myocardial infarction; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN B; CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; ADVERSE OUTCOME; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT;

EID: 78649402802     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2010.40.10.491     Document Type: Article

References (30)

1. Lee CK. Lipoprotein(a), Lp(a). Korean Circ J 1993;23:631-3.
2. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein (a) modulation of endothelial surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5.
3. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acd Sci U S A 1989;86:3847-51.
4. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acd Sci USA 1992;89:10193-7.
5. Park SH, Shin GJ. Lipoprotein (a) as a risk factor for coronary heart disease: whether related with NlDDM or not. Korean Circ J 1996;26:507-13.
6. Jürgens G, Taddei-Peters WC, Költringer P, et al. Lipoprotein (a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995;26:1841-8.
7. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000;102:1082-5.
8. Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein (a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008;117:176-84.
9. Foody JM, Milberg JA, Pearce GL, Sprecher DL. Lipoprotein (a) associated with coronary artery disease in older women: age and gender analysis. Atherosclerosis 2000;153:445-51.
10. Jenner JL, Ordovas JM, Lamonfava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein (A) levels: the Framingham Offspring Study. Circulation 1993;87:1135-41.
11. Seman LJ, Breckenridge WC. Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). Biochem Cell Biol 1986;64:999-1009.
12. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipemic subjects treated with nicotinic-acid. J Intern Med 1989;226:271-6.
13. Morishita R, Ishii J, Kusumi Y, et al. Association of serum oxidized lipoprotein (a) concentration with coronary artery disease: potential role of oxidized lipoprotein (a) in the vascular wall. J Atheroscler Thromb 2009;16:410-8.
14. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989;80:1313-9.
15. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003;49:1785-96.
16. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995;274:1771-4.
17. Insull W Jr, McGovern ME, Schrott H, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004;164:1121-7.
18. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein (a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein (a) transgenic mice. Circulation 2008;118:743-53.
19. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-35.
20. Hearn JA, Donohue BC, Báalbaki H, et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:736-9.
21. Desmarais RL, Sarembock IJ, Ayers CR, Velmon SM, Powers ER, Gimple LW. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403-9.
22. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma lipoprotein (a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998;98:1172-7.
23. Rhew JY, Jeong MH, Hong YJ, et al. The effects of lipoprotein (a) on coronary stent restenosis. Korean Circ J 2001;31:476-83.
24. Hoffmann R, Minz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996;94:1247-54.
25. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 1993;260:1655-8.
26. Morita Y, Himeno H, Yakuwa H, Usui T. Serum lipoprotein (a) level and clinical coronary tenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a). Circ J 2006;70:156-62.
27. Sim DS, Kim JH, Jeong MH. Differences in clinical outcomes between patients with ST-elevation versus non-ST-elevation acute myocardial infarction in Korea. Korean Circ J 2009;39:297-303.
28. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein (a). Clin Chem 2000;46:1956-67.
29. Kim CJ, Kwak MH, Kim KM, Ryu WS, Park JT, Ryoo UH. Lipoprotein (a) as an acute phase reactant. Korean J Lipidol 1996;6:111-5.
30. Heinemann K, Rübig A, Strothmann A, Nahum GG, Heinemann LA. Prevalence and opinions of hormone therapy prior to the Women's Health Initiative: a multinational survey on four continents. J Womens Health 2008;17:1151-66.